Harnessing the power of Bioluminescence Prolume is a biotechnology company whose core business is based upon newly discovered genes from deep water marine bioluminescent organisms. This has broad applications for biomedical research, drug discovery, and entertainment.

Prolume has cloned and patented several genes from bioluminescent marine organisms that encode fluorescent and luminescent proteins. The company seeks to license these genes to companies for use in biomedicine and biotechnology – as components of platform technologies and as research or diagnostic reagents. Prolume’s three green fluorescent proteins (GFPs) from marine anthozoans (Renilla mulleri, Renilla reniformis and Ptilosarcus) are intrinsically brighter than any other GFPs on the market, including the brightest variants of the well-known Aequorea GFP. Prolume’s GFPs have many potential uses in diverse areas such as drug discovery and biomedical research; high throughput screening (HTS); fluorescence activated cell sorting (FACS); transgenic reporting of gene expression in cells, animals and plants; environmental and process monitoring; and many proteomics applications, including protein biochips, and dynamic monitoring of protein interactions using FRET or BRET. Prolume is also currently developing a patented copepod luciferase (Gaussia princeps) that is exceptionally bright, small and biochemically robust. The company is seeking licensees/collaborators to help realize the great technical potential of this enzyme. Prolume also synthesizes bulk quantities of coelenterazine, the luciferin natively utilized by the photoprotein Aequorin and many luciferases, including those of Renilla reniformis and Gaussia. Prolume sells coelenterazine into both wholesale and end-user markets. Prolume also holds broad patents covering the use of bioluminescent proteins in consumer products, including foods and beverages, toys and novelties, and entertainment and education applications. The company is interested in partners and investors for the long-term development of bioluminescent products for these consumer markets.

Prolume NanoLight

NanoLight® Technology is the technology division of Prolume® Ltd., a company focusing upon broad based applications of marine bioluminescence. The NanoLight® division is dedicated to providing scientists with the highest quality reagents, luciferins (NanoFuel®s), recombinant bioluminescent proteins luciferases (NanoLight®s), photoproteins (NanoFlashTM) and fluorescent proteins (NanoFluorsTM).

We hope to offer the scientific, biotechnology and pharmaceutical communities brighter and color shifted luciferases and fluorescent proteins. We have a very easy licensing policy for non-profit as well as commercial entities.

NanoLight® Technology:

NanoLight® Luciferase Vectors

NanoFuel® Luciferins, Luciferases & Reagents

NanoFluorTM GFP Vectors

NanoTools® IPTG, DTT, Antioxidants and more

NanoLight® Technologies is a division of Prolume Ltd., formed by Prolume's founder Dr. Bruce Bryan and a group of excellent co-founders from Prolume® Ltd. namely Byron Ballou PhD; Gene Finely MD; Chris Szent-Gyorgyi PhD; Randall Murphy PhD and Miroslav Trampota.

Nanolight® Technology is a biotechnology company developing broad applications of natural, light-emitting marine proteins, or marine bioluminescence. The NanoLight division is focused on becoming the leader in high-value reagent & reporter systems for new product development in the pharmaceutical, agrichemical, and research products industries.

Valuable life science uses for NanoLight®’s technology include high-throughput drug discovery, functional genomics, tumor imaging, replacement of radioisotopes, and molecular diagnostics. One particularly exciting application is the ability to use NanoLight®’s reporter systems to “illuminate” gene and molecular function within living cells, allowing pharmaceutical companies a revolutionary method to study drug activity. A second opportunity is to broadly supply researchers who are increasingly moving away from radioactive reagents toward light-based reporter systems and instruments. NanoLight® Technologies is poised to capitalize on both of these accelerating market trends.

Aequorea victoriaNanoLight’s competitive advantage is based on three crucial proprietary positions:

Access to the novel bioluminescent and fluorescent protein molecules.

World’s lowest-cost production technology for coelenterazine (NanoFuel™), necessary for light emission.

World's largest collection of expression libraries from marine bioluminescent organisms.

These proprietary technologies, which NanoLight has already developed or protected by patent filings & trade secrets, permit the company to grow into the dominant supplier of proprietary bioluminescent reagents and reporter systems to the life science markets. NanoLight® can immediately provide partners access to:

Novel GFP genes isolated from Ptilosarcus gurneyi and Renilla Mulleri with distinctive properties including a novel chromophore sequence that differs in 3 of 6 residues from the Aequorea GFP.

Novel marine luciferases cloned from Renilla Mulleri, Pleuromama sp., and Gaussia sp., the latter appears to be brighter than existing Renilla or Firefly systems in mammalian cells.

Pending patents on the novel use of bioluminescent proteins on silicon chips for inexpensive high throughput screening and diagnostic applications.

cDNA libraries from over forty (40) different luminescent organisms for further gene discovery patenting, and licensing.

Proprietary functional screening methods to identify new bioluminescent genes.

This enormous genetic resource represents an outstanding opportunity for leading life sciences companies racing to establish advanced high-throughput screening and diagnostic systems.


沪公网安备 31011202007338号